Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
NCT ID: NCT01556828
Last Updated: 2016-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
70 participants
OBSERVATIONAL
2011-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Integrated Whole-Genome Analysis of Hematologic Disorders
NCT01108159
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
NCT00020072
Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin
NCT00066664
Cell-free Circulating DNA in Primary Cutaneous Lymphomas
NCT02883517
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
NCT02215928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient meets the clinical and/or pathologic criteria for the cutaneous or hematologic disorder being examined.
* Patient is willing to provide skin biopsies and five 10 mL tubes of peripheral blood.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Khavari, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University, School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SU-03142012-9329
Identifier Type: OTHER
Identifier Source: secondary_id
21750
Identifier Type: OTHER
Identifier Source: secondary_id
LYMNHL0091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.